FDA Expert Panel Urges Descheduling Testosterone: Major Push for Easier Access and Updated Labeling On December 10, 2025, an FDA-convened expert panel discussed significant updates to testosterone therapy regulations, with strong support for FDA testosterone descheduling by removing its Schedule III controlled substance status, expanding indications, and revising labels to reflect modern evidence. Bottom line…
Read more
FDA Panel Urges Testosterone Descheduling and Easier TRT Access





